SCHEDULE: Tang Capital Discloses 7.9% Stake in Keros Therapeutics

Tang Capital Management and affiliated entities have reported a 7.9% passive ownership stake in Keros Therapeutics, Inc. as of October 15, 2025.

Summary

• Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, and Tang Capital Partners International, LP collectively reported beneficial ownership of 2,418,984 shares of Keros Therapeutics, Inc. Common Stock.
• This represents a 7.9% stake in the company, based on 30,466,069 shares outstanding as of October 17, 2025, as referenced in a Tender Offer statement filed on Form Schedule TO.
• All reporting persons share both voting and dispositive power over these 2,418,984 shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of Keros Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The disclosure of a significant passive stake by a reputable investment firm like Tang Capital Management is generally viewed as a positive signal, indicating investor confidence in the company's long-term prospects, though it does not provide operational or financial performance details.

Positives

• A significant passive investment by Tang Capital Management and its affiliates indicates confidence in Keros Therapeutics, Inc. as an investment.
• The disclosure of a substantial institutional stake can attract further investor interest and potentially improve market liquidity.

Negatives

• No direct negatives are present in this passive ownership disclosure.

Risks

• The filing itself does not detail company-specific risks for Keros Therapeutics, Inc.
• The reporting persons explicitly state that the shares were not acquired for the purpose of changing or influencing control, mitigating risks associated with activist investor intervention.

Industry Context

This filing indicates a significant passive investment by a capital management firm in Keros Therapeutics, a company operating in the biotechnology or pharmaceutical sector, which often sees substantial institutional investment due to its growth potential and research-intensive nature.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 7.9% stake may positively influence market perception and potentially increase trading liquidity.
• Company Management: Awareness of a substantial passive investor may influence strategic decisions, though the investor has certified no intent to control.

Key Dates

Keywords

Keros Therapeutics, Tang Capital Management, Kevin Tang, Schedule 13G, beneficial ownership, common stock, passive investment, biotech, pharmaceutical